(Q36212328)

English

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

multiple sclerosis

0 references

author name string

H-P Hartung

1

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

F Munschauer

2

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

H Schellekens

3

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

588-601

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Epitope specificity of neutralizing antibodies against IFN-beta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Factor VIII immunogenicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Assessment of the antigenic response in humans to a recombinant mutant interferon beta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Human antibodies to recombinant factor VII in hemophiliacs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Inhibitor antibodies to factor VIII and factor IX: management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

The antigenicity of insulin: a review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Immunogenicity and allergenic potential of animal and human insulins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01104.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2005.01104.X

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36212328&oldid=1624296651"